Infliximab in the treatment of Crohn’s disease

The recent introduction of infliximab, a chimeric monoclonal antibody against tumor necrosis factor-α, has greatly modified the treatment of Crohn’s disease (CD). Data from the literature show encouraging results after intravenous infusion both for closure of intestinal or perianal fistulas and for...

Descripción completa

Detalles Bibliográficos
Autores principales: Poggioli, Gilberto, Laureti, Silvio, Campieri, Massimo, Pierangeli, Filippo, Gionchetti, Paolo, Ugolini, Federica, Gentilini, Lorenzo, Bazzi, Piero, Rizzello, Fernando, Coscia, Maurizio
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936311/
https://www.ncbi.nlm.nih.gov/pubmed/18360638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936311/
https://www.ncbi.nlm.nih.gov/pubmed/18360638

Ejemplares similares